Robert Thompson

Robert Thompson is the current CEO of Clinical Reference Laboratory, Inc. and has previously held positions as the CEO of Sandel Avionics, Emerge Diagnostics Inc., and eScreen. Robert has a wealth of experience in the diagnostics and pre-employment services industry, and has been instrumental in turning around and growing companies.

Thompson began their career in 2000 as the Chief Executive Officer of OraSure Technologies. In just two years, they were able to grow the company from $10 million to $32 million through strong sales and marketing execution. In September 2000, they negotiated and completed a merger with STC Technologies, forming Orasure Technologies. This added $14 million in profitable revenues, an oral fluid drug testing product line, and assay development capabilities to the company. Robert also achieved $4 million in merger synergies against a target of $2 million.

In 2002, they became the CEO of eScreen, where they successfully turned around the company and grew it into the largest, most technologically advanced player in the industry. Under their leadership, revenue grew from $28 million in 2002 to $160 million in 2012, with last three years averaging over 35% growth per year. This translated into substantial EBITDA growth – with last three years averaging over 60% growth per year. The company was sold to Alere in 2012 for $270 million and further contingent considerations.

Most recently, Thompson has been serving as the CEO of Clinical Reference Laboratory, Inc. Robert has continued their track record of success in this role, growing the company and positioning it for continued success in the future.

Robert Thompson has a Masters of Business Administration from Harvard Business School and a BSE from the University of Pennsylvania in Finance and Management.

Some direct reports include Heather Fehling - Chief Scientific Officer, Molecular Diagnostics & VP of Laboratory Sciences, James Sotos - VP of Wellness, and Dan Wittman - VP of Employer Services.